Unknown

Dataset Information

0

Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.


ABSTRACT: The μ opioid receptor (OR), a member of the class A subfamily of G-protein coupled receptors (GPCRs), is a major target for the treatment of pain. G-protein biased μ-OR agonists promise to be developed as analgesics. Thus, TRV130, the first representative μ-OR ligand with G-protein bias, has entered into phase III clinical trials. To identify the detailed G-protein-biased activation and inactivation mechanisms of the μ-OR, we constructed five μ-OR systems that were in complexes with the G-protein-biased agonists TRV130 and BU72, the antagonists β-FNA and naltrexone, as well as the free receptor. We performed a series of conventional molecular dynamics simulations and analyses of G-protein-biased activation and inactivation mechanisms of μ-OR. Our results, together with previously reported mutation results, revealed the operating mode of the activation switch composed of residues W6.48 and Y7.43 (Ballesteros/Weinstein numbering), the activity of which was responsible for down- and up-regulation, respectively, of the β-arrestin signaling, which in turn affected G-protein-biased activation of μ-OR. TRV130 was found to stabilize W6.48 by interacting with Y7.43. In addition, we obtained useful information regarding μ-OR-biased activation, such as strong stabilization of W7.35 through a hydrophobic ring interaction in the TRV130 system. These findings may facilitate understanding of μ-OR biased activation and the design of new biased ligands for GPCRs.

SUBMITTER: Cheng JX 

PROVIDER: S-EPMC5758664 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.

Cheng Jian-Xin JX   Cheng Tao T   Li Wei-Hua WH   Liu Gui-Xia GX   Zhu Wei-Liang WL   Tang Yun Y  

Acta pharmacologica Sinica 20171130 1


The μ opioid receptor (OR), a member of the class A subfamily of G-protein coupled receptors (GPCRs), is a major target for the treatment of pain. G-protein biased μ-OR agonists promise to be developed as analgesics. Thus, TRV130, the first representative μ-OR ligand with G-protein bias, has entered into phase III clinical trials. To identify the detailed G-protein-biased activation and inactivation mechanisms of the μ-OR, we constructed five μ-OR systems that were in complexes with the G-protei  ...[more]

Similar Datasets

| S-EPMC8541911 | biostudies-literature
| S-EPMC8640941 | biostudies-literature
| S-EPMC9322534 | biostudies-literature
| S-EPMC6645658 | biostudies-literature
| 2336583 | ecrin-mdr-crc
| S-EPMC3400840 | biostudies-literature
| S-EPMC11243066 | biostudies-literature
| S-EPMC6439305 | biostudies-literature
| S-EPMC5034817 | biostudies-literature
| S-EPMC7792944 | biostudies-literature